We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Targeted Nanogels Specifically Transport siRNA into Ovarian Cancer Cells

By LabMedica International staff writers
Posted on 01 Mar 2010
Nanoparticles crafted from hydrogels (nanogels) have been coated with receptor-specific peptides and used to transport siRNA (small, interfering RNA) capable of inhibiting the synthesis of epidermal growth factor receptor (EGFR) into ovarian cancer cells.

Targeted cancer therapy by RNA interference is a relatively new approach that can be used to silence reversibly genes in vivo. More...
In this study, RNA interference technology was used to shut down the gene for EGFR in ovarian cancer cells. Removal of this gene had been shown previously to increase the sensitivity of cancer cells to chemotherapeutic agents.

Delivery of the nucleic acid fragment has been the main hurdle delaying the broad development of siRNA-based therapeutics. In the current study, investigators at the Georgia Institute of Technology (Atlanta, USA) have gotten around this problem by protecting siRNA particles by enclosing them within hydrogel nanoparticles (nanogels). The siRNA was specific for the gene that encodes EGFR, which is highly overexpressed in some types of ovarian cancer. To ensure that the nanogels targeted only cancer cells, they were coated with peptides specific for the EphA2 receptor. Once bound to EphA2 receptors within the cancer cells the particles slowly released the siRNA over a timescale of days, allowing it to have a therapeutic effect.

Results published in the January 11, 2010, online edition of the journal BMC Cancer revealed that treatment of EphA2 positive Hey cells with siRNA-loaded, peptide-targeted nanogels decreased EGFR expression levels and significantly increased the sensitivity of this cell line to docetaxel. Nanogel treatment of SK-OV-3 cells, which are negative for EphA2 expression, failed to reduce EGFR levels and did not increase docetaxel sensitivity.

"With our technique we are inhibiting EGFR's growth, with small interfering RNA. And by inhibiting its growth, we are increasing the cell's apoptotic function. If we hit the cell with chemotherapy at the same time, we should be able to kill the cancer cells more effectively,” said senior author Dr. John McDonald, professor of biology at the Georgia Institute of Technology. "The fact that this system is releasing the siRNA slowly, without giving the cell time to immediately recover, gives us much better efficiency at killing the cancer cells with chemotherapy.”

Related Links:
Georgia Institute of Technology




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.